Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma
{{output}}
Neoadjuvant immunotherapy (NIT) is transforming the treatment landscape for esophageal squamous cell carcinoma (ESCC), substantially improving the pathological complete response (pCR) rates achieved with traditional chemoradiotherapy. Clinical trials demonstra... ...
